COMPANY
Clinical Phase 2
Keywords: directed evolution protein therapeutics antibody MDK-703
Location: San Diego, CA · source · Oct 13, 2026
Profile checked Oct 10, 2026
Timeline
- Trial start Phase 1/Phase 2: A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors source ↗
- Trial start Phase 1: A Single Ascending Dose Study to Evaluate MDK-703 in Healthy Adult Volunteers source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT05366634 | A Single Ascending Dose Study to Evaluate MDK-703 in Healthy Adult Volunteers | Phase 1 | Completed | Jun 30, 2022 | Dec 28, 2022 (actual) |
| NCT05716295 | A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors | Phase 1/Phase 2 | Terminated | Feb 8, 2023 | Apr 30, 2024 (actual) |
